The original version of this Letter contains an error in Figure 5, concerning an experiment performed at University of Bologna, which shows the effect of the tested compounds on microglial activation. In the incorrect published Figure 5, the GAPDH band (housekeeping protein used as loading control) from a preliminary experiment for compound 1 was accidentally shown, and the correct image is used below. Furthermore, since we used the same LPS-treated control microglial cells for compounds 11 and 12, being that they were tested in the same experiment and plate, the right two panels have been modified for clarity. This is the correct Figure 5:.(Figure Presented).
Correction: Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent to Combat Alzheimer's Disease (ACS Medicinal Chemistry Letters (2019) 10: 4 (469−474) DOI: 10.1021/acsmedchemlett.8b00507)
De Simone A.;Betari N.;Daniele S.;Petralla S.;Casadei R.;Davani L.;Frabetti F.;Montanari S.;Tumiatti V.;Monti B.;Andrisano V.;Milelli A.
2019
Abstract
The original version of this Letter contains an error in Figure 5, concerning an experiment performed at University of Bologna, which shows the effect of the tested compounds on microglial activation. In the incorrect published Figure 5, the GAPDH band (housekeeping protein used as loading control) from a preliminary experiment for compound 1 was accidentally shown, and the correct image is used below. Furthermore, since we used the same LPS-treated control microglial cells for compounds 11 and 12, being that they were tested in the same experiment and plate, the right two panels have been modified for clarity. This is the correct Figure 5:.(Figure Presented).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
